|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
4/15/2010 3:40:50 PM
MISSISSAUGA, Ontario, April 14, 2010 – Cipher Pharmaceuticals Inc. (TSX: DND) today announced it will hold its Annual and Special Meeting of Shareholders on Thursday, April 22, 2010 at 4:30 p.m. ET.
WHAT: Annual and Special Meeting of Shareholders
WHERE: Toronto Board of Trade
1 First Canadian Place
Toronto, Ontario
WHEN: Thursday, April 22, 2010 at 4:30 p.m. ET.
The meeting will be webcast live. To access the webcast go to:
http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2998160
Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher’s strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher’s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company’s lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).
|
|
|
|
|
|
|
|
|
|
|